Relmada Therapeutics, Inc. RLMD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.02M-14.4% | $26.88M-9.8% | $29.81M-19.3% | $36.92M-17.6% | $44.82M-2.9% | ||
| $37.33M+15.8% | $32.22M+14.9% | $28.04M-16.6% | $33.6M-2.0% | $34.3M-9.1% | ||
| $60.34M+2.1% | $59.1M+2.2% | $57.84M-18.0% | $70.52M-10.9% | $79.12M-5.7% | ||
| -$60.34M-2.1% | -$59.1M-2.2% | -$57.84M+18.0% | -$70.52M+10.9% | -$79.12M+5.7% | ||
| $1.47M-14.5% | $1.72M+2.8% | $1.67M-38.6% | $2.72M-20.4% | $3.41M-12.8% | ||
| -$58.88M-2.6% | -$57.39M-2.2% | -$56.17M+17.2% | -$67.81M+10.4% | -$75.71M+5.3% | ||
| -$1.11+24.5% | -$1.47+18.3% | -$1.80+18.9% | -$2.22+11.6% | -$2.51+5.3% | ||
| -$60.34M-2.1% | -$59.1M-2.2% | -$57.84M+18.0% | -$70.52M+10.9% | -$79.12M+5.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Relmada Therapeutics, Inc. profitable?
- Relmada Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.9M over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s earnings per share?
- Relmada Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.11.
- Where does Relmada Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.